Skip to main content

Published locations for Biosimilars and patients: Discussions should address safety, cost, and anxiety about change

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Biosimilars and patients: Discussions should address safety, cost, and anxiety about change

User login

  • Reset your password
  • /content/biosimilars-and-patients-discussions-should-address-safety-cost-and-anxiety-about-change
  • /edermatologynews/article/262133/business-medicine/biosimilars-and-patients-discussions-should
  • /familypracticenews/article/262133/business-medicine/biosimilars-and-patients-discussions-should
  • /internalmedicinenews/article/262133/business-medicine/biosimilars-and-patients-discussions-should
  • /pediatricnews/article/262133/business-medicine/biosimilars-and-patients-discussions-should-address
  • /rheumatologynews/article/262133/business-medicine/biosimilars-and-patients-discussions-should
  • /pediatrics/article/262133/business-medicine/biosimilars-and-patients-discussions-should-address
  • /rheumatology/article/262133/business-medicine/biosimilars-and-patients-discussions-should-address
  • /internalmedicine/article/262133/business-medicine/biosimilars-and-patients-discussions-should
  • /dermatology/article/262133/business-medicine/biosimilars-and-patients-discussions-should-address
  • /familymedicine/article/262133/business-medicine/biosimilars-and-patients-discussions-should-address